rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2023-151-157rsp-3317Research ArticleМЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙINTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASESВакцинация при ревматических заболеваниях: актуальные вопросы (по материалам рекомендаций ACR)Vaccination for rheumatic diseases: Current issues (based on ACR guidelines)https://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

belovbor@yandex.ruhttps://orcid.org/0000-0003-4327-6720МуравьеваН. В.MuravyevaN. V.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а; 119991, Москва, ул. Трубецкая, 8, стр. 2

115522, Moscow, Kashirskoye Highway, 34A;119991, Moscow, Trubetskaya str., 8, building 2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation202328042023612151157Copyright © Белов Б.С., Муравьева Н.В., Насонов Е.Л., 20232023Белов Б.С., Муравьева Н.В., Насонов Е.Л.Belov B.S., Muravyeva N.V., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3317

В современной ревматологии коморбидные инфекции оказывают значительное влияние на морбидность и летальность, особенно при иммуновоспалительных ревматических заболеваниях (ИВРЗ). Одним из путей решения указанной проблемы является изучение и активное применение различных вакцин. В настоящей статье проанализированы рекомендации по вакцинации больных ИВРЗ, предложенные в 2022 г. экспертами Американской коллегии ревматологов (ACR, American College of Rheumatology). Обсуждаются безопасность и иммуногенность вакцинации, связанной с предупреждением различных инфекций у больных ИВРЗ. Подчеркивается, что решение о приостановке применения препарата до или после вакцинации должно быть принято с учетом имеющегося ИВРЗ, его активности и риска вакциноуправляемой инфекции. Ключевым компонентом любой стратегии вакцинации (особенно для условных рекомендаций) является принятие решений совместно с пациентом. Обозначены основные направления будущих исследований по рассматриваемой проблеме.

In modern rheumatology, comorbid infections have a significant impact on morbidity and mortality, especially in immuno-inflammatory rheumatic diseases (IIRD). One of the ways to solve this problem is the study and active use of various vaccines. This article analyzes the recommendations for vaccination of patients with acute respiratory infections, proposed in 2022 by experts of the American College of Rheumatology (ACR). The safety and immunogenicity of vaccination associated with the prevention of various infections in patients with IVR are discussed. It is emphasized that the decision to suspend taking the drug before or after vaccination should be made taking into account the existing IIRD, its activity and the risk of vaccine-controlled infection. A key component of any vaccination strategy (especially for conditional recommendations) is decision-making together with the patient. The main directions of future research on the problem under consideration are outlined.

иммуновоспалительные ревматические заболеваниягрипппневмониягерпес-вирусные инфекциивирус папилломы человекажелтая лихорадкавакцинациярекомендацииimmuno-inflammatory rheumatic diseasesinfluenzapneumoniaherpesvirus infectionshuman papillomavirusyellow fevervaccinationrecommendationsСтатья подготовлена в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», № государственного задания 1021051503137-7.ReferencesBass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023;75(3):333-348. doi: 10.1002/art.42386Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023;75(3):333-348. doi: 10.1002/art.42386Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) recommendations. URL: https://www.cdc.gov/vaccines/acip/recommendations.html (Accessed: 10th January 2023).Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) recommendations. URL: https://www.cdc.gov/vaccines/acip/recommendations.html (Accessed: 10th January 2023).Kimberlin DW, Barnett ED, Lynfield R (eds). Red book: 2021–2024 report of the Committee on Infectious Diseases; 32nd ed. Itasca (IL):American Academy of Pediatrics;2021.Kimberlin DW, Barnett ED, Lynfield R (eds). Red book: 2021–2024 report of the Committee on Infectious Diseases; 32nd ed. Itasca (IL):American Academy of Pediatrics;2021.Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 5. Arthritis Rheumatol. 2023;75(1):E1-E16. doi: 10.1002/art.42372Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 5. Arthritis Rheumatol. 2023;75(1):E1-E16. doi: 10.1002/art.42372Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Askling J. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: How do they compare to those of COVID-19? Ann Rheum Dis. 2022;81(3):433-439. doi: 10.1136/annrheumdis-2021-221461Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Askling J. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: How do they compare to those of COVID-19? Ann Rheum Dis. 2022;81(3):433-439. doi: 10.1136/annrheumdis-2021-221461Bukhanova D, Belov B, Tarasova G, Erdes S, Dubinina T, Lukina G, et al. Assessment of efficacy and safety of a trivalent splitvirus influenza vaccine in patients with rheumatic diseases. Ann Rheum Dis. 2018;77(Suppl 2):1060-1061. doi: 10.1136/annrheumdis-2018-eular.1500Bukhanova D, Belov B, Tarasova G, Erdes S, Dubinina T, Lukina G, et al. Assessment of efficacy and safety of a trivalent splitvirus influenza vaccine in patients with rheumatic diseases. Ann Rheum Dis. 2018;77(Suppl 2):1060-1061. doi: 10.1136/annrheumdis-2018-eular.1500Stapleton JT, Wagner N, Tuetken R, Bellamy AR, Hill H, Kim S, et al. High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial. Vaccine. 2020;38(23):3934-3941. doi: 10.1016/j.vaccine.2020.04.002Stapleton JT, Wagner N, Tuetken R, Bellamy AR, Hill H, Kim S, et al. High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial. Vaccine. 2020;38(23):3934-3941. doi: 10.1016/j.vaccine.2020.04.002Colmegna I, Useche ML, Rodriguez K, McCormack D, Alfonso G, Patel A, et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: A randomised, double-blind, active-comparator trial. Lancet Rheumatol. 2020;1:14-23. doi: 10.1016/S2665-9913(19)30094-3Colmegna I, Useche ML, Rodriguez K, McCormack D, Alfonso G, Patel A, et al. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: A randomised, double-blind, active-comparator trial. Lancet Rheumatol. 2020;1:14-23. doi: 10.1016/S2665-9913(19)30094-3Watad A, Bragazzi NL, McGonagle D, Adawi M, Bridgewood C, Damiani G, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases. Clin Immunol. 2019;203:1-8. doi: 10.1016/j.clim.2019.03.007Watad A, Bragazzi NL, McGonagle D, Adawi M, Bridgewood C, Damiani G, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases. Clin Immunol. 2019;203:1-8. doi: 10.1016/j.clim.2019.03.007Буханова ДВ, Белов БС, Тарасова ГМ, Соловьев СК, Ананьева ЛП, Попкова ТВ, и др. Коморбидные инфекции при ревматических заболеваниях (по данным ФГБНУ НИИР им. В.А. Насоновой). Медицинский совет. 2019;9:86-91. doi: 10.21518/2079-701X-2019-9-86-91Bukhanova DV, Belov BS, Tarasova GM, Soloviev SK, Ananyeva LP, Popkova TV, et al. Comorbid infections in rheumatic diseases (according to FSBI RIR named after V.A. Nasonova). Medical Council. 2019;(9):86-91 (In Russ.). doi: 10.21518/2079-701X-2019-9-86-91Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. 2022. URL: https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf. (Accessed: 10th January 2023).Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. 2022. URL: https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf. (Accessed: 10th January 2023).Чучалин АГ, Брико НИ, Авдеев СН, Белевский АС, Биличенко ТН, Демко ИB, и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019;29(1):19-34. doi: 10.18093/0869-0189-2019-29-1-19-34Chuchalin AG, Briko NI, Avdeev SN, Belevskiy AS, Bilichenko TN, Demko IV, et al. Federal clinical guidelines on preventive vaccination against pneumococcal infections in adults. Pulmonologiya. 2019;29(1):19-34 (In Russ.). doi: 10.18093/0869-0189-2019-29-1-19-34Белов БС, Муравьева НВ, Тарасова ГМ, Баранова ММ, Сергеева МС, Черкасова МВ, и др. Вакцинопрофилактика пневмококковой инфекции при ревматических заболеваниях: 10-летний опыт применения в ФГБНУ НИИР им. В.А. Насоновой. Научно-практическая ревматология. 2022;60(3):261-266. doi: 10.47360/1995-4484-2022-261-266Belov BS, Muravyeva NV, Tarasova GM, Baranova MM, Sergeeva MS, Cherkasova MV, et al. Pneumococcal vaccination in rheumatic diseases: 10 years of application experience at the V.A. Nasonova Research Institute of Rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022; 60(3):261-266 (In Russ.). doi: 10.47360/1995-4484-2022-261-266Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882Centers for Disease Control and Prevention. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: Updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. URL: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm?s_cid=mm7104a1_w (Accessed: 10th January 2023).Centers for Disease Control and Prevention. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: Updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. URL: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm?s_cid=mm7104a1_w (Accessed: 10th January 2023).Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: Implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328-2337. doi: 10.1002/art.39670Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: Implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328-2337. doi: 10.1002/art.39670Kwan A, Rayes HA, Lazova T, Anderson N, Bonilla D, Su J, et al. Herpes zoster in SLE: Prevalence, incidence and risk factors. Lupus Sci Med. 2022;9(1):e000574. doi: 10.1136/lupus-2021-000574Kwan A, Rayes HA, Lazova T, Anderson N, Bonilla D, Su J, et al. Herpes zoster in SLE: Prevalence, incidence and risk factors. Lupus Sci Med. 2022;9(1):e000574. doi: 10.1136/lupus-2021-000574Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, et al.; Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: A phase 3, randomized clinical trial. Clin Infect Dis. 2020;70(2): 181-190. doi: 10.1093/cid/ciz177Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, et al.; Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: A phase 3, randomized clinical trial. Clin Infect Dis. 2020;70(2): 181-190. doi: 10.1093/cid/ciz177Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, et al.; ZOE-HSCT Study Group Collaborators. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial. JAMA. 2019;322(2):123-133. doi: 10.1001/jama.2019.9053Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, et al.; ZOE-HSCT Study Group Collaborators. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial. JAMA. 2019;322(2):123-133. doi: 10.1001/jama.2019.9053Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al.; Zoster-039 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-XDagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al.; Zoster-039 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-XLenfant T, Jin Y, Kirchner E, Hajj-Ali RA, Calabrese LH, Calabrese C. Safety of recombinant zoster vaccine: A retrospective study of 622 rheumatology patients. Rheumatology. 2021;60(11):5149-5157. doi: 10.1093/rheumatology/keab139Lenfant T, Jin Y, Kirchner E, Hajj-Ali RA, Calabrese LH, Calabrese C. Safety of recombinant zoster vaccine: A retrospective study of 622 rheumatology patients. Rheumatology. 2021;60(11):5149-5157. doi: 10.1093/rheumatology/keab139Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus. 2017;26(7):682-689. doi: 10.1177/0961203316672928Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus. 2017;26(7):682-689. doi: 10.1177/0961203316672928Kim SC, Schneeweiss S, Liu J, Karlson EW, Katz JN, Feldman S, et al. Biologic disease-modifying antirheumatic drugs and risk of high-grade cervical dysplasia and cervical cancer in rheumatoid arthritis: A cohort study. Arthritis Rheumatol. 2016;68(9):2106-2113. doi: 10.1002/art.39689Kim SC, Schneeweiss S, Liu J, Karlson EW, Katz JN, Feldman S, et al. Biologic disease-modifying antirheumatic drugs and risk of high-grade cervical dysplasia and cervical cancer in rheumatoid arthritis: A cohort study. Arthritis Rheumatol. 2016;68(9):2106-2113. doi: 10.1002/art.39689Dhar JP, Essenmacher L, Dhar R, Magee A, Ager J, Sokol RJ. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine. 2017;35(20):2642-2646. doi: 10.1016/j.vaccine.2017.04.001Dhar JP, Essenmacher L, Dhar R, Magee A, Ager J, Sokol RJ. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine. 2017;35(20):2642-2646. doi: 10.1016/j.vaccine.2017.04.001Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: A case-control study. Ann Rheum Dis. 2013;72(5):659-664. doi: 10.1136/annrheumdis-2012-201393Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: A case-control study. Ann Rheum Dis. 2013;72(5):659-664. doi: 10.1136/annrheumdis-2012-201393Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease – A prospectively controlled vaccination study. Rheumatology (Oxford). 2012;51(4):695-700. doi: 10.1093/rheumatology/ker389Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease – A prospectively controlled vaccination study. Rheumatology (Oxford). 2012;51(4):695-700. doi: 10.1093/rheumatology/ker389Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: Implications for clinical practice. Ann Rheum Dis. 2011;70(12):2144-2147. doi: 10.1136/ard.2011.152983Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: Implications for clinical practice. Ann Rheum Dis. 2011;70(12):2144-2147. doi: 10.1136/ard.2011.152983Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. Ann Rheum Dis. 2017;76(9):1559-1565. doi: 10.1136/annrheumdis-2017-211128Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. Ann Rheum Dis. 2017;76(9):1559-1565. doi: 10.1136/annrheumdis-2017-211128Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. Ann Rheum Dis. 2018;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. Ann Rheum Dis. 2018;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222Наумцева МС, Белов БС, Александрова ЕН, Тарасова ГМ, Новиков АА, Каратеев ДЕ, и др. Иммуногенность и безопасность 23-валентной полисахаридной пневмококковой вакцины у больных ревматоидным артритом: результаты двухлетнего наблюдения. Научно-практическая ревматология. 2016;6:674-680. doi: 10.14412/1995-4484-2016-674-680Naumtseva MS, Belov BS, Aleksandrova EN, Tarasova GM, Novikov AA, Karateev DE, et al. Immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatoid arthritis: Results of a two-year followup study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(6):674-680 (In Russ.). doi: 10.14412/1995-4484-2016-674-680Буханова ДВ, Белов БС, Тарасова ГМ, Эрдес Ш, Дубинина ТВ, Лукина ГВ, и др. Эффективность, безопасность и иммуногенность трехвалентной инактивированной сплит-вакцины против гриппа у пациентов с ревматическими заболеваниями. Медицинский совет. 2018;12:106-110. doi: 10.21518/2079-701X-2018-12-106-110Bukhanova DV, Belov BS, Tarasova GM, Erdes S, Dubinina TV, Lukina GV, et al. Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases. Medical Council. 2018;(12):106-110 (In Russ.). doi: 10.21518/2079-701X-2018-12-106-110Тарасова ГМ, Белов БС, Черкасова МВ, Асеева ЕА, Решетняк ТМ, Попкова ТВ, и др. Иммунизация 23-валентной полисахаридной пневмококковой вакциной пациентов с системной красной волчанкой, получавших комбинированную иммуносупрессивную терапию. Эффективная фармакотерапия. 2021;17(36):6-12. doi: 10.33978/2307-3586-2021-17-36-6-12Tarasova GM, Belov BS, Cherkasova MV, Aseyeva YeA, Reshetnyak TM, Popkova TV, et al. Immunization with 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus receiving combined immunosuppressive therapy. Effective Pharmacotherapy. 2021;17(36):6-12 (In Russ.). doi: 10.33978/2307-3586-2021-17-36-6-12Tarasova G, Egorova O, Reshetnyak T, Belov B. Tolerability and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic vasculitis, preliminary results. Ann Rheum Dis. 2022; 81(Suppl 1):1435. doi: 10.1136/annrheumdis-2022-eular.1487Tarasova G, Egorova O, Reshetnyak T, Belov B. Tolerability and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic vasculitis, preliminary results. Ann Rheum Dis. 2022; 81(Suppl 1):1435. doi: 10.1136/annrheumdis-2022-eular.1487Valim V, Machado KLLL, Miyamoto ST, Pinto AD, Rocha PCM, Serrano EV, et al. Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: A prospective non-interventional study. Front Immunol. 2020;11:1382. doi: 10.3389/fimmu.2020.01382Valim V, Machado KLLL, Miyamoto ST, Pinto AD, Rocha PCM, Serrano EV, et al. Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: A prospective non-interventional study. Front Immunol. 2020;11:1382. doi: 10.3389/fimmu.2020.01382Wieten RW, Jonker EF, Pieren DK, Hodiamont CJ, van Thiel PP, van Gorp EC, et al. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccines receiving immunosuppressive medication. Vaccine. 2016;34(10):1247-1251. doi: 10.1016/j.vaccine.2016.01.037Wieten RW, Jonker EF, Pieren DK, Hodiamont CJ, van Thiel PP, van Gorp EC, et al. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccines receiving immunosuppressive medication. Vaccine. 2016;34(10):1247-1251. doi: 10.1016/j.vaccine.2016.01.037Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384-1387. doi: 10.1136/ard.2006.063586Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384-1387. doi: 10.1136/ard.2006.063586Curtis JR, Cofield SS, Bridges SL Jr, Bassler J, Deodhar A, Ford TL, et al. The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: A randomized controlled trial. Ann Intern Med. 2021;174(11):1510-1518. doi: 10.7326/M20-6928Curtis JR, Cofield SS, Bridges SL Jr, Bassler J, Deodhar A, Ford TL, et al. The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy: A randomized controlled trial. Ann Intern Med. 2021;174(11):1510-1518. doi: 10.7326/M20-6928Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-e100. doi: 10.1093/cid/cit684Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-e100. doi: 10.1093/cid/cit684Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immunemediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50-74. doi: 10.1177/1203475418811335Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immunemediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50-74. doi: 10.1177/1203475418811335Centers for Disease Control and Prevention. Altered immunocompetence. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/immunocompetence.html (Accessed 10th January 2023).Centers for Disease Control and Prevention. Altered immunocompetence. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/immunocompetence.html (Accessed 10th January 2023).Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16(1):99-105. doi: 10.1016/j.cgh.2017.08.041Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16(1):99-105. doi: 10.1016/j.cgh.2017.08.041Chiarella-Redfern H, Lee S, Jubran B, Sharifi N, Panaccione R, Constantinescu C, et al. Suboptimal vaccination administration in mothers with inflammatory bowel disease and their biologicexposed infants. Inflamm Bowel Dis. 2022;28(1):79-86. doi: 10.1093/ibd/izab033Chiarella-Redfern H, Lee S, Jubran B, Sharifi N, Panaccione R, Constantinescu C, et al. Suboptimal vaccination administration in mothers with inflammatory bowel disease and their biologicexposed infants. Inflamm Bowel Dis. 2022;28(1):79-86. doi: 10.1093/ibd/izab033Lee KE, Jung SA, Park SH, Moon CM, Shim SY, Kim ES, et al. Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity. Intest Res. 2019;17(2):237-243. doi: 10.5217/ir.2018.00071Lee KE, Jung SA, Park SH, Moon CM, Shim SY, Kim ES, et al. Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity. Intest Res. 2019;17(2):237-243. doi: 10.5217/ir.2018.00071Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5(6):555-558. doi: 10.1016/j.crohns.2011.05.006Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5(6):555-558. doi: 10.1016/j.crohns.2011.05.006Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev Vaccines. 2016;15(2):239-256. doi: 10.1586/14760584.2016.1115351Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev Vaccines. 2016;15(2):239-256. doi: 10.1586/14760584.2016.1115351Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643-1648. doi: 10.1016/j.vaccine.2010.12.072Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643-1648. doi: 10.1016/j.vaccine.2010.12.072Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 2014;178(1):40-47. doi: 10.1111/cei.12390Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 2014;178(1):40-47. doi: 10.1111/cei.12390Koch J, Harder T, von Kries R, Wichmann O. Risk of intussusception after rotavirus vaccination. Dtsch Arztebl Int. 2017;114(15):255-262. doi: 10.3238/arztebl.2017.0255Koch J, Harder T, von Kries R, Wichmann O. Risk of intussusception after rotavirus vaccination. Dtsch Arztebl Int. 2017;114(15):255-262. doi: 10.3238/arztebl.2017.0255Centers for Disease Control and Prevention. Timing and spacing of immunobiologics. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#:_:text=Two%20or%20more%20injectable%20or,the%20potential%20risk%20for%20interference (Accessed: 10th January 2023).Centers for Disease Control and Prevention. Timing and spacing of immunobiologics. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#:_:text=Two%20or%20more%20injectable%20or,the%20potential%20risk%20for%20interference (Accessed: 10th January 2023).

The authors declare that there are no conflicts of interest present.